JP2022532996A5 - - Google Patents
Info
- Publication number
- JP2022532996A5 JP2022532996A5 JP2021563352A JP2021563352A JP2022532996A5 JP 2022532996 A5 JP2022532996 A5 JP 2022532996A5 JP 2021563352 A JP2021563352 A JP 2021563352A JP 2021563352 A JP2021563352 A JP 2021563352A JP 2022532996 A5 JP2022532996 A5 JP 2022532996A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- isolated polynucleotide
- vector
- immune cells
- polynucleotide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025063227A JP2025109712A (ja) | 2019-04-26 | 2025-04-07 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839455P | 2019-04-26 | 2019-04-26 | |
| US62/839,455 | 2019-04-26 | ||
| US202063005041P | 2020-04-03 | 2020-04-03 | |
| US63/005,041 | 2020-04-03 | ||
| PCT/US2020/029775 WO2020219848A1 (en) | 2019-04-26 | 2020-04-24 | Rituximab-resistant chimeric antigen receptors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063227A Division JP2025109712A (ja) | 2019-04-26 | 2025-04-07 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532996A JP2022532996A (ja) | 2022-07-21 |
| JP2022532996A5 true JP2022532996A5 (https=) | 2023-04-28 |
| JP7664180B2 JP7664180B2 (ja) | 2025-04-17 |
Family
ID=70847489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563352A Active JP7664180B2 (ja) | 2019-04-26 | 2020-04-24 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
| JP2025063227A Pending JP2025109712A (ja) | 2019-04-26 | 2025-04-07 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063227A Pending JP2025109712A (ja) | 2019-04-26 | 2025-04-07 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11896617B2 (https=) |
| EP (2) | EP3959235B1 (https=) |
| JP (2) | JP7664180B2 (https=) |
| KR (1) | KR20220004076A (https=) |
| CN (1) | CN113728001B (https=) |
| AU (2) | AU2020263495B2 (https=) |
| BR (1) | BR112021021178A2 (https=) |
| CA (1) | CA3134308A1 (https=) |
| CO (1) | CO2021014121A2 (https=) |
| DK (1) | DK3959235T5 (https=) |
| ES (1) | ES2961314T3 (https=) |
| FI (1) | FI3959235T3 (https=) |
| IL (1) | IL287487A (https=) |
| MX (1) | MX2021012820A (https=) |
| MY (1) | MY204280A (https=) |
| PE (1) | PE20212369A1 (https=) |
| PH (1) | PH12021552415A1 (https=) |
| SA (1) | SA521430654B1 (https=) |
| SG (1) | SG11202111031RA (https=) |
| TW (1) | TWI865517B (https=) |
| WO (1) | WO2020219848A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY204419A (en) * | 2017-10-31 | 2024-08-28 | Servier Lab | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells |
| CA3198363A1 (en) * | 2020-10-09 | 2022-04-14 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods and compositions comprising pd1 chimeric polypeptides |
| EP4271817A2 (en) | 2020-12-30 | 2023-11-08 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| CN120712097A (zh) * | 2022-10-20 | 2025-09-26 | 微克立思尔私人有限公司 | 免疫疗法中细胞因子释放综合征的减轻 |
| EP4604966A1 (en) * | 2022-10-20 | 2025-08-27 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| AU2023362745A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in |
| AU2023362746A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| JP2025535441A (ja) * | 2022-10-20 | 2025-10-24 | マイクロ クリスパー プライベート リミテッド | 免疫療法におけるサイトカイン放出症候群の軽減 |
| CN119700678A (zh) * | 2024-12-19 | 2025-03-28 | 武汉大学 | 一种司妥昔纳米球的合成及其偶联car-t细胞的方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| RU2305708C2 (ru) | 2001-10-02 | 2007-09-10 | Энститю Клейтон Де Ля Решерш | Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение |
| WO2007137300A2 (en) | 2006-05-23 | 2007-11-29 | Bellicum Pharmaceuticals, Inc. | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2012209103B2 (en) | 2011-01-26 | 2015-12-03 | Takeda Pharmaceutical Company Limited | Methods and compositions for the synthesis of multimerizing agents |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| BR112014029417B1 (pt) * | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| DK2956175T3 (da) | 2013-02-15 | 2017-11-27 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| FI2997141T3 (fi) | 2013-05-13 | 2022-12-15 | CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä | |
| EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| AU2015214145A1 (en) | 2014-02-04 | 2016-08-25 | Kite Pharma. Inc. | Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof |
| US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| MX2017002205A (es) * | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| AU2015312117A1 (en) * | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
| BR112017013981A2 (pt) | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| GB201518792D0 (en) * | 2015-10-23 | 2015-12-09 | Univ Manchester | Production of proteins |
| EP3390432B1 (en) | 2015-12-18 | 2020-09-23 | Ucl Business Ltd | Treatment |
| JP2019509738A (ja) | 2016-03-11 | 2019-04-11 | ブルーバード バイオ， インコーポレイテッド | ゲノム編集された免疫エフェクター細胞 |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| GB201609597D0 (en) | 2016-06-01 | 2016-07-13 | Univ Sheffield | Therapy |
| CA3025667A1 (en) * | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| KR102746901B1 (ko) * | 2017-03-03 | 2024-12-26 | 옵시디안 테라퓨틱스, 인크. | Cd19 조성물 및 면역요법을 위한 방법 |
| AU2018246377B2 (en) * | 2017-03-31 | 2025-01-30 | Cellectis Sa | Universal anti-CD22 chimeric antigen receptor engineered immune cells |
| US20210189361A1 (en) | 2018-04-23 | 2021-06-24 | Duke University | Downregulation of snca expression by targeted editing of dna-methylation |
| US20210213119A1 (en) * | 2018-08-28 | 2021-07-15 | Immunotech Biopharm Co., Ltd. | Improved therapeutic t cell |
-
2020
- 2020-04-24 SG SG11202111031RA patent/SG11202111031RA/en unknown
- 2020-04-24 EP EP20728258.3A patent/EP3959235B1/en active Active
- 2020-04-24 JP JP2021563352A patent/JP7664180B2/ja active Active
- 2020-04-24 BR BR112021021178A patent/BR112021021178A2/pt unknown
- 2020-04-24 MX MX2021012820A patent/MX2021012820A/es unknown
- 2020-04-24 US US16/857,573 patent/US11896617B2/en active Active
- 2020-04-24 AU AU2020263495A patent/AU2020263495B2/en active Active
- 2020-04-24 CN CN202080031593.1A patent/CN113728001B/zh active Active
- 2020-04-24 FI FIEP20728258.3T patent/FI3959235T3/fi active
- 2020-04-24 MY MYPI2021005771A patent/MY204280A/en unknown
- 2020-04-24 PE PE2021001764A patent/PE20212369A1/es unknown
- 2020-04-24 PH PH1/2021/552415A patent/PH12021552415A1/en unknown
- 2020-04-24 WO PCT/US2020/029775 patent/WO2020219848A1/en not_active Ceased
- 2020-04-24 KR KR1020217036085A patent/KR20220004076A/ko active Pending
- 2020-04-24 CA CA3134308A patent/CA3134308A1/en active Pending
- 2020-04-24 TW TW109113823A patent/TWI865517B/zh active
- 2020-04-24 ES ES20728258T patent/ES2961314T3/es active Active
- 2020-04-24 EP EP23186544.5A patent/EP4295851A3/en active Pending
- 2020-04-24 DK DK20728258.3T patent/DK3959235T5/da active
-
2021
- 2021-10-21 SA SA521430654A patent/SA521430654B1/ar unknown
- 2021-10-21 IL IL287487A patent/IL287487A/en unknown
- 2021-10-22 CO CONC2021/0014121A patent/CO2021014121A2/es unknown
-
2023
- 2023-12-26 US US18/395,996 patent/US12447178B2/en active Active
-
2025
- 2025-04-07 JP JP2025063227A patent/JP2025109712A/ja active Pending
- 2025-12-11 AU AU2025279733A patent/AU2025279733A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532996A5 (https=) | ||
| Tsuji et al. | Generation of tumor-specific, HLA class I–restricted human Th1 and Tc1 cells by cell engineering with tumor peptide–specific T-cell receptor genes | |
| EP3240805B1 (en) | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 | |
| Kalos et al. | Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology | |
| JP2022109953A5 (https=) | ||
| FI3959235T3 (fi) | Rituksimabiresistenttejä kimeerisiä antigeenireseptoreja ja niiden käyttö | |
| CN108055847A (zh) | T细胞受体 | |
| WO2020086989A1 (en) | Increase or maintaining t-cell subpopulations in adoptive t-cell therapy | |
| US20230227575A1 (en) | Engineered T Cells | |
| US20250333762A1 (en) | Cell-specific transcriptional regulatory sequences and uses thereof | |
| CN114127287A (zh) | 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法 | |
| AU2019356414B2 (en) | Binding proteins specific for HA-1H and uses thereof | |
| JP2015092865A (ja) | ヒト化抗ｃｄ２０キメラ抗原レセプター | |
| JP2025508371A (ja) | Ｓｔｅａｐ１に結合するキメラ抗原受容体 | |
| US20240009235A1 (en) | T cell receptors directed against bob1 and uses thereof | |
| RU2021134337A (ru) | Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения | |
| CN114891815A (zh) | Dna片段、表达载体、嵌合抗原受体t细胞、应用 | |
| CN113929767A (zh) | 具有高亲和力的t细胞受体及其用途 | |
| US20240417443A1 (en) | Il5ra cell surface markers | |
| Philip | RQR8: A universal safety switch for cellular therapies | |
| AU2024358609A1 (en) | Means and methods for delivery of agents to immune effector cells | |
| JP2026501830A (ja) | 遺伝子操作ｔ細胞 | |
| HK40115184A (en) | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 | |
| JP2025539364A (ja) | 遺伝子操作ｔ細胞 | |
| CN117903312A (zh) | 靶向gcc的抗体及其应用 |